Evidence map›Paper›PMID 35117900›Full record

ArticleTranslational cancer research2020

shRNA targeting PLK1 inhibits the proliferation and invasion of nasopharyngeal carcinoma cells.

Yan Zhou, Chu Wu, Bingxue Liu, Juan Zhu, Yating Zhong, Yuqing Yuan, Yue Huang, Yunlian Tang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yan ZhouCancer Research Institute, Medical College of Hengyang, Key Laboratory of Tumor Cellular & Molecular Pathology, University of South China, Hengyang, China.
Chu WuCancer Research Institute, Medical College of Hengyang, Key Laboratory of Tumor Cellular & Molecular Pathology, University of South China, Hengyang, China.
Bingxue LiuCancer Research Institute, Medical College of Hengyang, Key Laboratory of Tumor Cellular & Molecular Pathology, University of South China, Hengyang, China.
Juan ZhuCancer Research Institute, Medical College of Hengyang, Key Laboratory of Tumor Cellular & Molecular Pathology, University of South China, Hengyang, China.
Yating ZhongDepartment of Pathology, The First People's Hospital of Changde City, Changde, China.
Yuqing YuanCancer Research Institute, Medical College of Hengyang, Key Laboratory of Tumor Cellular & Molecular Pathology, University of South China, Hengyang, China.
Yue HuangCancer Research Institute, Medical College of Hengyang, Key Laboratory of Tumor Cellular & Molecular Pathology, University of South China, Hengyang, China.
Yunlian TangCancer Research Institute, Medical College of Hengyang, Key Laboratory of Tumor Cellular & Molecular Pathology, University of South China, Hengyang, China.
University of South China · CNThe First People's Hospital of Changde · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPolo-like kinase 1 (PLK1) is a serine/threonine protein kinase, which has been studied as a potential gene therapy target for many years. PLK1 is overexpressed in a variety of tumors, and its expression often negatively correlated with patient prognosis. However, the role of PLK1 in nasopharyngeal carcinoma (NPC) is rarely studied.

methodsTwo recombinant vector plasmids were transfected into CNE2 cell lines by liposome transfection, CNE2/PLK1 shRNA target PLK1 mRNA, as well as a non-targeting control plasmid, CNE2/NC shRNA. Meanwhile, non-transfected cells (CNE2) were also used as controls. Real-time quantitative PCR (qRT-PCR) and Western blotting were performed to detect the transfection effect. The effects of the downregulation of PLK1 on cell biological behavior was evaluated

resultsPLK1 mRNA and protein were significantly inhibited in CNE2/PLK1 shRNA cells. Compared to control groups, the CNE2/PLK1 shRNA cells showed slower cell growth and a significantly decreased cell-cloning rate. Both migration and invasion were significantly inhibited in experimental cells. The proportions of G2-phase and apoptotic cells within the experimental group were significantly increased.

conclusionsOur results indicate that specific interference of

Indexed as

biological behaviordown-regulationnasopharyngeal carcinoma (NPC)Polo-like kinase 1 (PLK1)targeted therapy

Identifiers

PMID35117900
PMCPMC8798612
OpenAlexW3047719367

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.